Skip to content

Drug interactions

Finerenone + Pazopanib

Severity: Moderate

Finerenone and Pazopanib: moderate interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Pazopanib is a weak CYP3A4 inhibitor and may modestly increase finerenone exposure. This could increase the risk of hyperkalemia.

What this interaction means in plain words

Finerenone and Pazopanib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.

Finerenone belongs to Cardiovascular; Pazopanib belongs to Oncology.

Evidence level: Moderate

Why it happens

Weak inhibition of CYP3A4 reduces finerenone clearance.

What to do

Check serum potassium and renal function when starting or changing either drug. Adjust or hold finerenone if potassium rises.

What to ask your pharmacist

  • Should I take them at different times of day?
  • Does the dose of either medicine need to change?
  • Is there anything I should avoid, such as alcohol or certain foods, while on both?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Finerenone and Pazopanib, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 7 days on the web. No card needed.

Frequently asked questions

Can I take Finerenone with Pazopanib?

MediHelp rates the interaction as moderate. Finerenone and Pazopanib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Pazopanib is a weak CYP3A4 inhibitor and may modestly increase finerenone exposure. This could increase the risk of hyperkalemia.

How serious is the interaction between Finerenone and Pazopanib?

MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Check serum potassium and renal function when starting or changing either drug. Adjust or hold finerenone if potassium rises.

What other medicines interact with Pazopanib?

MediHelp also lists interactions of Pazopanib with, for example, Adagrasib, Amiodarone, Amisulpride. The full list is on the Pazopanib page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in